News

Medium_zyngenia

Zyngenia, Inc. reports successful preclinical evaluation of a novel bispecific antibody

A novel bispecific antibody targeting TNF and Ang2 was evaluated in Biomedcode’s Tg197 model

Read More
Medium_address

Biomedcode is a partner in aDDRess an international Initial Training Network

The aDDRess ITN is a joint European program with a focus on the impact of Chromatin Dynamics on the DNA damage Response (DDR)

Read More
Medium_codeage

Biomedcode is a partner in CodeAge an international Initial Training Network

CodeAge is a research network focusing on molecular, cellular and systems biology aspects of ageing.

Read More
Medium_tarkinaid

Biomedcode is a participant in TARKINAID a research project to fight chronic autoimmune diseases

TARKINAID an international consortium of organisations from EU & Brazil, develops new ways of treating chronic autoimmune diseases such as RA

Read More
Medium_theralead

Biomedcode is a participant in TheRalead a National funded research project

TheRAlead aims to exploit a “hit to lead” pipeline to develop novel therapeutics targeting arthritis

Read More
Medium_avesthagen

Successful completion of AVENT preclinical efficacy trial using Biomedcode's Tg197 model of arthritis

AVESTHAGEN announced that it has successfully completed the pre-Clinical efficacy trial for one of its biosimilar drugs AVENT .

Read More
Medium_viron

Viron Therapeutics Inc. announced successful preclinical testing of VT-346 using Biomedcode's TG197 model

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study.

Read More
Medium_astrazeneka

In February 2010, Biomedcode agreed the non-exclusive out-licensing of one of its proprietary animal models...

In February 2010, Biomedcode agreed the non-exclusive out-licensing of one of its proprietary animal models to AstraZeneca under undisclosed terms....

Read More